Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitorin vitroand confer resistance to nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani, Hiroshi Mohri, Bruce Culbertson, et al.
Nature (2022) Vol. 613, Iss. 7944, pp. 558-564
Open Access | Times Cited: 306
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Seyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, et al.
Science Advances (2023) Vol. 9, Iss. 13
Open Access | Times Cited: 126
SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 678
Open Access | Times Cited: 102
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 75
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani, Hiroshi Mohri, Bruce Culbertson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 43
Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies
Shuiyun Lan, Grace Neilsen, Ryan L. Slack, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 22
The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms
Carlos A. Ramos‐Guzmán, Milorad Andjelkovic, Kirill Zinovjev, et al.
Chemical Science (2023) Vol. 14, Iss. 10, pp. 2686-2697
Open Access | Times Cited: 21
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 34
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Seyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 31
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
JCI Insight (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 30
Large library docking for novel SARS‐CoV‐2 main protease non‐covalent and covalent inhibitors
Elissa A. Fink, Conner Bardine, Stefan Gahbauer, et al.
Protein Science (2023) Vol. 32, Iss. 8
Open Access | Times Cited: 20
A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2
Karen Sargsyan, Karine Mazmanian, Carmay Lim
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 15
A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
Zhanwei Du, Lin Wang, Yuan Bai, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 5
Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections
Anton Petcherski, Brett M Tingley, Andrew Martin, et al.
Life Science Alliance (2025) Vol. 8, Iss. 4, pp. e202403182-e202403182
Open Access
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
Claudia Alteri, Valeria Fox, Rossana Scutari, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 22
The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses
Beata Pająk, Rafał Zieliński, John T. Manning, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 5928-5928
Open Access | Times Cited: 21
A guide to COVID‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV‐2 infection
Drugan K. Brady, Aashi R. Gurijala, Liyu Huang, et al.
FEBS Journal (2022) Vol. 291, Iss. 8, pp. 1632-1662
Open Access | Times Cited: 19
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo
James A. Torchia, Alexander H. Tavares, Laura Stentoft Carstensen, et al.
Science Advances (2022) Vol. 8, Iss. 49
Open Access | Times Cited: 19
Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed −1 ribosomal frameshifting
Carmine Varricchio, Gregory Mathez, Trestan Pillonel, et al.
Antiviral Research (2022) Vol. 208, pp. 105452-105452
Open Access | Times Cited: 14
Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction
Young Soo Kim, Eun-Bin Kwon, Buyun Kim, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12516-12516
Open Access | Times Cited: 12
Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs
Lena Parigger, A. Krassnigg, Tobias Schopper, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 12
Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 10
Sierra SARS-CoV-2 sequence and antiviral resistance analysis program
Philip L. Tzou, Kaiming Tao, Malaya K. Sahoo, et al.
Journal of Clinical Virology (2022) Vol. 157, pp. 105323-105323
Open Access | Times Cited: 10
Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease
Julia M. Flynn, Qiu Yu J. Huang, Sarah N. Zvornicanin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top